Ankylosing Spondylitis

July 08, 2021

Atul Deodhar, MD, MRCP, discusses his recent study investigating the efficacy and safety of upadacitinib in active ankylosing Spondylitis, including study design, results, and its clinical significance.

July 01, 2021

The US Food and Drug Administration (FDA) has delayed its decision on upadacitinib (RINVOQ) for the for the treatment of adults with active psoriatic arthritis and adults with active ankylosing spondylitis.

April 22, 2021

Investigators discovered that women with axial spondyloarthritis (axSpA) have an overall higher disease burden and more peripheral manifestations when compared with men. They further theorized that awareness of these differences and the way the condition presents differently in both sexes may be used to more easily identify axSpA and improve disease management.

October 06, 2020

Despite major advances in axial spondyloarthritis and an increasing number of therapeutic options, questions remain related to the optimized treatment strategies and to the individual drug choice, according to a review published in Current Rheumatology Reports.

November 27, 2019

Nearly one-quarter of patients with ankylosing spondylitis experienced disease progression over time, with male sex, presence of baseline damage, active disease state, and higher inflammatory markers predictive of spinal progression, while treatment with tumor necrosis factor (TNF) inhibitors slowed the progression rate, say researchers recently writing in Arthritis Care & Research.

October 08, 2019

The oral therapy filgotinib could be a more effective treatment for patients with active ankylosing spondylitis who fail treatment with NSAIDs, according to the results of a study presented at the Clinical Congress of Rheumatology West in San Diego last month.

August 30, 2019

Lilly has announced that it received FDA approval for Taltz (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis).

August 20, 2019

An Indian-made biosimilar to adalimumab has been shown to be safe and effective for up to 24 weeks in patients with ankylosing spondylitis, say researchers writing in ACR Open Rheumatology this month.

August 01, 2019

New research shows that a newly identified species of gut bacteria is significantly depleted in patients with ankylosing spondylitis.

August 01, 2019

High levels of comorbidity burden are associated independently with poor physical function and increased disability in patients with psoriatic arthritis, however, patients ankylosing spondylitis did not report worse function when comorbidities were present.